

Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable remissions, and a favorable safety...
You can purchase shares of Senti Biosciences (NASDAQ:SNTI) through any online brokerage.
Other companies in Senti Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Senti Biosciences has a consensus price target of $11.25.
The stock price for Senti Biosciences (NASDAQ: SNTI) is $0.195 last updated October 23, 2026 at 4:38 PM EDT.
There are no upcoming dividends for Senti Biosciences.
Senti Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Senti Biosciences.
Senti Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created...